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ABSTRAK
Tujuan: untuk menganalisis penanda biologi CXCR4, IL11-RA, TFF1 dan MLF1P, klinikopatologi dan profil 
ekspresi genetik mRNA sebagai penanda peningkatan kejadian metastasis tulang pada pasien kanker payudara 
stadium lanjut. Metode: studi ini merupakan penelitian potong lintang. Analisis dilakukan pada total 92 pasien 
kanker payudara, terdiri atas 46 pasien metastasis tulang dan 46 pasien dengan metastasis nontulang. Analisis 
imunohistokimia dan microarray, dilakukan pada 81 sampel formalin fixed paraffin embedded (FFPE) dari 
81 pasien yang didapat. Data dikumpulkan melalui rekam medis, pemeriksaan imunohistokimia (IHK), dan 
microarray dengan nanoString nCounterTM. Hasil: artikel ini merupakan bagian satu dari dua tahap pelaporan 
hasil penelitian. Pada tahap satu diperoleh hasil analisis IHK, IL11-RA dengan cut-off ≥103,5 menunjukkan 
peningkatan kejadian metastasis tulang, dengan OR 3,803 (95 % interval kepercayaan [IK], 1,375-10,581), 
p=0,010, dan MLF1P dengan cut-off ≥83,0 menunjukkan peningkatan kejadian metastasis tulang, dengan OR 
2,784 (95% IK, 1,009-7,681), p=0,048. Status ER+ menunjukkan peningkatan kejadian metastasis tulang, 
dengan OR 7,640 (95 % IK, 2,599-22,459), p<0,000. AUC gabungan IL-11RA, MLF1P dan ER+, mempunyai 
ketepatan hampir 80% (meningkat dibandingkan AUC masing-masing secara terpisah), untuk membedakan dan 
menjelaskan kejadian metastasis tulang, pada kanker payudara stadium lanjut. Kesimpulan: IL11-RA, MLF1P 
dan ER+, merupakan determinan peningkatan kejadian metastasis tulang pasien kanker payudara stadium lanjut.
Kata kunci: ER+, ESR1, IL11-RA, MLF1P, nanoString, profil ekspresi genetik.
ABSTRACT
Aim: to analyze expression of biomarkers CXCR4, IL11-RA, TFF1 and MLF1P, and clinicopathology in 
advanced breast cancer patients with bone metastatic. Methods: this is a cross-sectional study. Analysis was done 
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against a total of 92 breast cancer patients, including 46 bone metastatic patients and 46 non-bone metastatic 
patients. Immunohistochemistry and microarray analysis was performed in 81 formalin fixed paraffin embedded 
(FFPE) samples from 81 patients were used. Data were collected through medical records, immunohistochemistry 
(IHC), and microarray with nanoString nCounterTM. Results: this article is part one of a two stage reporting 
research results. In part one we got the results of the IHC analysis, IL11-RA with cut-off ≥103.5 showed OR 3.803 
(95 % confidence interval [CI], 1.375-10.581), p=0.010, MLF1P with cut-off ≥83.0 OR 2.784 (95% CI, 1.009-
7.681), p=0.048, and ER+ OR 7.640 (95 % CI, 2.599-22.459), p<0.000, were associated with bone metastastic 
incidences in advanced breast cancer, and were statistically significantly different. A combination of IL-11RA, 
MLF1P and ER+, showed an accuracy of approaching 80% to discriminate between bone metastatic and non bone 
metastatic in advanced breast cancer patients. Conclusion: IL11-RA, MLF1P, and ER+ were the determinants 
that were associated with increasing bone metastasis incidence.
Keywords: breast cancer, metastatic bone disease, ER+, ESR1, IL11-RA, MLF1P.
INTRODUCTION
Breast cancer is the second leading cause of 
cancer death in women, and it is the top cancer 
among women in developed countries. For the 
last few years, breast cancer has become the 
leading cancer type on a global level.1-4 Breast 
cancer mortality is mostly related to distant 
metastasis to other vital organs. Approximately 
30-40% of breast cancer recurrence cases 
involved bone metastasis, while some autopsy 
studies report bone involvement in 70% of 
breast cancer related mortality. Previous study 
conducted in Dharmais cancer hospital showed 
a 24.4% bone metastasis incidence in advanced 
stage breast cancer. St Gallen consensus reported 
14.9% and 40.8% cumulative incidence of bone 
metastasis in node positive breast cancer 2 and 
10 years after diagnosis.5,6
Breast cancer is a heterogenous malignancy 
with complex and not fully understood mechanism. 
Anatomy variance, multiple clinicopathology 
and molecular biology factors still are unable 
to explain nor predict the possibility of bone 
metastasis. Cancer metastasis to certain organs, 
including bone is not a random event and we 
believed it proceeds in a systematic sequence.7 
Cancer cells are able to survive because of its 
capability to express normal genes related to bone, 
and by doing so, cancer cells has the ability to 
survive and proliferate in bone microenvironment. 
For example, osteopontin (OPN) produced by 
cancer is closely related to poor prognosis and 
survival.8
Certain subtypes such as intrinsic luminal 
breast cancer is well known to relapse not until 
20 years after first being diagnosed and treated, 
and differs from HER-2 subtype and TNBC that 
have the tendency to relapse within the first 5 
years of treatment.9,10 Studies have discovered 
several immunohistochemistries as an early 
bone metastasis marker. Guise et al. discovered 
that PTHrP may have a role in osteolytic breast 
cancer process.11 Kang et al.12 found IL-11, 
CXCR-4, MMO-1, ostepontin and FGF5 have 
their own role in bone metastasis event such as 
angiogenesis, homing, invasion and osteolysis, 
yet those findings are not completely valid and 
some studies were inconsistent due to complex 
molecular base. There are no publications 
yet, covering clinicopathology, and biologic 
marker in breast cancer, that are able to identify 
valid factors that are related or can predict the 
possibility of a bone metastasis event.
METHODS
This  is  a  cross-sect ional  s tudy to 
evaluate expression of biologic markers, and 
clinicopathology in advanced breast cancer 
cases. This study first started in July 2012 and 
lasted until February 2015. This study has 
received approval from the ethics committee of 
the Medical Faculty of Universitas Indonesia, 
MTA (Material Transfer Agreement) from the 
Ministry of Health and this study was conducted 
in agreement with the declaration of Helsinki.
This study recruited 92 subjects with 
advanced breast cancer based on study criteria. 
Study subjects consisted of 46 bone metastasis 
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patient and 46 nonbone metastasis patient 
from 3 hospitals in Jakarta mostly collected 
from Cipto Mangunkusumo Hospital, Mochtar 
Riady Comprehensive Cancer Centre and 
Darmais Cancer Hospital. Pathology results 
were reviewed by staff of Pathology Department 
Medical Faculty University of Indonesia, who 
were specifically assigned.
This article is part one of a two stage 
reporting research. In part one we got the 
results of the immunohistochemistry (IHC) 
analysis and part two is microarray RNA 
expression. Formalin fixed paraffin embedded 
(FFPE) cutting result, optimation process, IHC 
examination dan result evaluation were done twice 
including supervised and validation. Intensity 
and immunohistochemistry evaluation were 
conducted againts CXCR-4, IL11RA, MLF1P and 
TFF-1. Results were scored based on 300 tumor 
cells from 5 HPF (High Power Field) 400 time 
magnification of light microscope, using H-score 
formula=Σ(Pi x i) or H-score=(% intensity of 
stained cell 1x1) + (% intensity of stained cell 
2x2) + (% intensity of stained cell 3x3).13
Clinicopathology and microarray RNA 
expression data were obtained from medical and 
pathology records as per-operational definition 
and conducted at the National Cancer Center 
Singapore using NanoString nCounterTM 
protocol as per recommendation http://www.
nanostring.com/support/video_nCounter_gex_
protocol.php Editing process were conducted 
before data entry. Data were analyzed using 
SPSS for Windows v.20 (SPSS Inc, USA). Data 
analysis included univariate analysis to evaluate 
data distribution, bivariate analysis using Chi-
square test or Fischer and multivariate analysis 
using logistic regression test. Variable tested in 
multivariate analysis were the ones with p value 
<0.25 during bivariate analysis.
RESULTS
Ninety two FFPE samples consisting of 46 
cases of bone metastase and 46 case of nonbone 
metastasis were evaluated from 274 advanced 
breast cancer, collected from 6 major hospitals 
in Jakarta.
Tumor size and node status were not analyzed 
since most of the sample size were unmeasureable 
(subcutaneous lesion, bone lytic lesion, etc) 
and the node size were only based on clinical 
impression. Most, clinicopathology factor were 
not associated with a bone metastasis event (p 
value >0,050) but age >65 years, ductal invasive, 
low malignancy degree and relapse had higher 
bone metastases risk. Positive ER status (p value 
<0.001) and luminal subtype (p value=0.019) 
had higher risk rate, as well as PR positive 
had 2.5 times higher bone metastases risk than 
PR negative (p=0.033). However, PR+ and 
luminal type were not statistically significant (p 
value=0.055) in multi regression analysis, because 
of their interaction to ER+.
Evaluation of CXCR4, IL11-RA, TFF1 dan 
MLF1P with cut-off >200 showed no significant 
difference. We then analyzed to determine 
the optimal cut-off value. Receiver operating 
characteristic (ROC) was used to obtain cut-off 
value. Based on that analysis, we obtain a good 
area under the curve (AUC) on IL11-RA and 
MLF1P with each value of 0.652 and 0.670 and 






Figure 1. ROC with area under the curve (AUC) for 
prospective gene expression in breast cancer in: a) IL11-RA 
(AUC=0.652), b) MLF1P (AUC=0.670)
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Table 1. Association of clinicopathology variable and immunohistochemistry with bone metastase and non bonemetastase 
in advanced breast cancer patient
Metastasis
OR (95% CI) p*
Bone, n (%) Non-bone, n (%)
Clinicopathology
Age
 - > 64 3 (33.3) 6 (66.7) 0.500 (0.105-2.379) 0.384
 - 55 - 64 years 8 (47.1) 9 (52.9) 0.889 (0.270-2.925) 0.846
 - 45 - 54 years 20 (55.6) 16 (44.4) 1.250 (0.473-3.303) 0.653
 - 35- 44 years 15 (50.0) 15 (50.0) Reff
Histopathologi
 - Ductal Invasive/NST 37 (50.7) 36 (49.3) 1.142 (0.415-3.137) 1.000
 - Lobular Invasive 9 (47.4) 10 (52.6) Reff
Malignancy degree
 - Low 13 (43.3) 17 (56.7) 0.328 (0.070-1.518) 0.154
 - Intermediate 26 (50.0) 26 (50.0) 0.429 (0.099-1.841) 0.255
 - High 7 (70.0)   3 (30.0) Reff
 - Primary/ relapse
 - Primary 25 (43.9) 32 (56.1) 0.521(0.222-1.225) 0.198
 - Relapse 21 (60.0) 14 (40.0) Reff
Immunohistochemistry
Estrogen (ER)
 - Positive 39 (66.1) 20 (33.9) 7.243 (2.682-19.561) < 0.001
 - Negative 7 (21.2) 26 (78.8) Reff
Progesteron (PR)
 - Positive 33 (58.9) 23 (41.1) 2.538 (1.070-6.021) 0.033
 - Negative 13 (36.1) 23 (63.9) Reff
HER-2
 - High expression 15 (40.5) 22 (59.5) 0.528 (0.227-1.229) 0.202
 - Low expression 31 (56.4) 24 (43.6) Reff
Molecular subtype
 - Luminal 39 (58.2) 28 (41.8) 3.582 (1.319-9.726) 0.019
 - TNBC 0 (0.0) 8 (100.0) - 0.006
 - HER-2 7 (41.2) 10 (58.8) 0.646 (0.222-1.878) 0.591
CXCR4
 -  ≥190.0 32 (55.2) 26(44.6) 1.758 (0.746-4.142) 0.280
 - <190.0 14 (41.2) 20 (58.8) Reff
IL11-RA
 -  ≥103.5 33 (58.9) 23 (41.1) 2.538 (1.070-6.021) 0.033
 - <103.5 13 (36.1) 23 (63.9) Reff
TFF1
 - ≥153.0 28 (53.8) 24 (46.2) 1.426 (0.623-3.263) 0.528
 - <153.0 18 (45.0) 22 (55.0) Reff
MLF1P
 -  ≥83.0 35 (60.9) 23 (39.7) 3.182 (1.306-7.752) 0.018 
 - < 83.0 11 (32.4) 23 (67.6) Reff
Chi square test, if p< 0.05, indicates significant statistic differences; Reff: represent group with the lowest risk
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Analysis result showed statistically 
significant difference on variables IL11-RA 
(p=0.033) and MLF1P (p=0.018) as shown 
in Table 1. In the high cut-off value group, 
IL11-RA (cut-off ≥103.5) and MLF1P (cut-off 
≥83.0), each had 2.54 and 3.18 times more bone 
metastasis risk compared to the low cut-off value 
group variabel (Table 1), that has p<0.25, and 
which was analyzed using multivariate analysis 
with logistic regression. Those variable were 
ER, PR, HER-2, IL11-RA, MLF1P, degree of 
tumor grade, and primary/relapse type. Luminal 
subtype variable were not analyzed further 
in multivariate analysis as part of positive 
interaction from estrogen positive.
Result of multivariate analysis showed that 
variables having significant association (p<0.05) 
with bone metastasis incidence in breast cancer 
were ER, IL11-RA, and MLF1P, as shown on 
Table 2.
Multivariate analysis yielded odds ratio 
(OR) 3.803 for IL11-RA, which means that 
breast cancer patients with IL11-RA ≥103.5 have 
almost four times the risk for bone metastasis 
compared to breast cancer patient with gene 
expression <103,5. This also applies for MLF1P 
≥ 83.0 which showed 2.784 times higher risk 
for bone metastasis compared to <83.0. Result 
of multivariate analysis showed that variables 
having significant association (p<0.05) with bone 
metastasis incidence in breast cancer were ER+, 
IL11-RA, and MLF1P, as shown on Table 2.
Further, statistically significant variable 
in multivariate analysis, i.e. ER, MLF1P, and 
IL11-RA were analyzed using combined ROC 
curve for the three variables. The result showed 
that AUC for combination of ER, IL11-RA, 
and MLF1P was 0.80 in which better than each 
variable alone.
DISCUSSION
The main complication of breast cancer is 
the metastasis of cancer cells to surrounding 
tissues or other organs. It is known that the 
majority of primary cancer cells have the ability 
to circulate all the time and only few of it can 
survive specifically.14 It is estimated that around 
40% to 75% cases of breast cancer have bone 
metastasis.3,6,15,16 The mechanism of metastasis 
of breast cancer cells to the bone is a complex 
process, involving proliferation, invasion, 
adhesion, and colonization in the bone.17 This 
mechanism can only be done by breast cancer 
cells with specific characteristics and function, 
by interaction of cancer cells with molecules, 
growth factors, chemokines, and receptors which 
can did homing to the bone.
Table 2. Logistic regression for clinicopathology and immunohistochemistry variables with bone metastasis incidence in 
breast cancer
Variables Coef. (B) SE (B) P* OR (IK 95%)
Early Model 
 - ER (+) 1.917 0.726 0.008 6.799 (1.637-28.233)
 - PR (+) 0.071 0.638 0.911 1.074 (0.307-3.751)
 - HER-2 (high) -0.343 0.655 0.601 0.710 (0.197-2.564)
 - IL11-RA (≥103,5) 1.331 0.564 0.018 3.786 (1.254-11.436)
 - MLF1P (≥83,0) 1.280 0.607 0.035 3.598 (1.095-11.827)
 -  Tumor grade (rendah) -1.658 0.935 0.076 0.191 (0.031-1.190)
 - Tumor  grade(moderate) -0.853 0.640 0.183 0.426 (0.122-1.493)
 - Primer/Relaps (primer) -1.024 0.598 0.087 0.359 (0.111-1.160)
Final Model
 - ER (+) 2.033 0.550 0.000 7.640 (2.599-22.459)
 - IL11-RA (≥103,5) 1.336 0.519 0.010 3.803 (1.375-10.518)
 - MLF1P (≥83,0) 1.024 0.518 0.048 2.784 (1.009-7.681)
Multi regression logistic test, if p<0.05, implies statiscally significance
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Based on clinicopathology data shown on 
Table 1, there was no significant difference for 
each variable (age, histopathology, grading, and 
tumor status, i.e. primary or recurrent). Around 
72% of breast cancer patients were under 54 
years, with age ranging from 45 to 54 years. 
The IBCSG (International Breast Cancer Study 
Group) study involving 6.792 breast cancer 
patients revealed that 55.6 % were above 50 
years, whereas 25.6% were above 60 years.18 The 
result implies that our study showed tendency to 
a younger age distribution, which is also found in 
Pakistan, India, and Srilanka.3,19-21 The reason for 
difference in age distribution is not known, but it 
is suggested that ethnic, geographic nutrition, and 
genetic factors could possibly be the underlying 
factors.
Breast cancer patients with recurrent tumor 
have higher bone metastasis proportion (60%) 
than non-bone metastasis (40%). The recurrence 
indicates that the tumor has been treated and 
grew within a certain time period, and has the 
potential to change genetic characteristics and 
expression, thus eventually they tend to have 
metastasis to a particular secondary organ.22,23 
For primary tumors, the proportion of bone 
metastasis was lower (43.9%) compared to non-
bone metastasis (56.1%). The higher non-bone 
metastasis in primary tumor is probably due to 
bone metastasis genotype was covered by other 
genotypes with more aggressive characteristics, 
such as TNBC or HER2, thus they tend to have 
metastasis to other organs,such as: lung, liver, 
and brain.24-26
Our result was different with the study of 
Koizumi et al.27 which demonstrated that tumor 
size of 3 cm, positive lymph node, histopathologic 
type of invasive lobular and scirrhous have 
significant difference to bone recurrence in 
early stage, also with Mintempergher et al.28 
and Colleoni et al.18 who showed lymph node 
status had significant association with long term 
recurrence, especially bone. These different 
findings were due to our subjects who were 
in very advanced stage and mostly came with 
unmeasurable lesion, thus tumor size and lymph 
node status were not suitable as predicting factors 
for recurrence.
Estrogen, progesterone, and luminal 
molecular subtype have significant difference 
in bone metastasis group compared to non-
bone group, while HER2 showed insignificant 
difference. Similar result was shown by Wei B et 
al.29 and Wei S et al.30 demonstrating significant 
difference to positive increased estrogen in breast 
cancer patients with bone metastasis compared to 
non-bone metastasis. This result was consistent 
with NSABP B-14 findings, which showed 
higher ER expression as strong predictor for 
5-year-recurrency.9 Smid et al.31 found around 
two-thirds of patients with bone recurrence were 
luminal cases (ER+) and only 7% found in basal 
type tumor.
Ryungsa Kim et al.32 also showed no 
significant difference for HER2 and age, tumor 
size, grading, and histologic type between 
bone metastasis and non-bone metastasis. 
Furthermore, eleven patients (22.9%) with 
high expression of HER-2 showed insignificant 
increase of metastasis protein activated by HER-
2, such as c-Met, VEGF, CXCR4 and pAKt. This 
showed the possibility of different mechanisms 
of bone metastasis in high expression HER2 
cases. Although estrogen is known to have 
significant association with bone metastasis, the 
role of estrogen to bone metastasis still could not 
be explained completely.28,33
One explanation correlated ER with bone 
metastasis were overexpression of SRS+ 
(signature Src+).10,15,25 Src is a tyrosin kinase 
which plays a role in progressivity and metastasis 
of cancer cells with slow growth. Specifically, it 
causes long term recurrence. Increased activity 
of Src (SRS+) is a response to TRAIL signal and 
also AKT as a response to CXCL12 and IGFI 
which are expressed in the microenvironment of 
bone metastasis, i.e. bone marrow stroma, thus 
it escapes apoptosis. Those characteristics make 
Src regarded as a mediator for anti-apoptosis 
mechanism.10,15,25 Furthermore, Src increases 
activity of P3IK and Akt pathways as selective 
response to enrich primary tumor clonal which 
has the ablility for bone metastasis.
There were 3 requirements needed for a 
premetastatic selection to occur: hyperactive Src 
in primary tumor, heterogenous characteristic 
in primary tumor, and minimal concentration 
of CXCL12/IGFI as a selector for tumor cells 
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which will proliferate and survive.10 Author also 
realize than none of the seven previous study 
were included Src as gene predictor.
IL11-RA and MLF1P variables showed 
significant difference in bone and non-bone 
metastasis, while CXCR4 and TFF1 did not reveal 
significant difference. Thomassen et et al.34 proved 
that, MLF1P had significant difference on bone 
metastasis and consistently highly expressed, thus 
the gene remains a candidate for predictor gene to 
progresivity of cancer cells to bone. The MLF1P 
gene was bound to MLF1 which was a negative 
regulator of p53, coded by Tp53 gene. The 
gene has potency to disturb broad and complex 
functions of p53, including cells cycle “arrest”, 
apotosis, angiogenesis, and DNA repair.35
IL11-RAand IL11 were known to have 
association with tumor progressivity, cells 
growth, and differentiation from several 
malignant tumors.36,37 IL11 which was produced 
by various cells including bone marrow stromal 
as a response to inflammation will be bound to 
IL11-RA and then activate STAT3 pathway and 
facilitate EMT by breaking down ECM as an 
initial process of metastasis.38 This is consistent 
with findings of Smid et al.31 and Minn et 
al.39 which demonstrated that IL11, together 
with other genes such as OPN, CTGF, TTF, 
CXCR4, had significant roles to bone recurrence 
incidences. Kang et al.12 has also demonstrated 
that human breast cancer line, most of the gene 
with osteolytic function generally was expressed 
with a big difference. IL11 alone without 
RANKL, can directly induce osteoclast forming 
from the precursor in the bone marrow. IL11-RA 
can be found in cytoplasma and membrane, while 
IL11 is only found in cytoplasma.
All area under the curve (AUC) of those 
variables showed AUC less than 0.70, with 
smallest value of 0.537 and 0.603 in TFF1 and 
CXCR4 respectively. Those values showed the 
capability of TFF1 and CXCR4 to differentiate 
breast cancer patients which has been predicted to 
have unfavourable bone metastasis. Combination 
of ER+, MLF1P and IL11-RA yielded AUC 
almost 80% compared to separated IL11-
RA and MLF1P with AUC of 0.652 and 
0.670 respectively, which indicated that the 
combination of those factors yielded better 
performance to differentiate cases with bone 
and non-bone metastasis compared to individual 
factors.
CONCLUSION
There is an association between the high 
expression of biomarker IL 11-RA, MLF1P, 
and ER (+) with the increase in incidence of 
bone metastasis in advanced breast cancer. The 
combination of these markers resulted in AUC 
of almost 0.8, which can be used to differentiate 
between bones and non-bones metastasis.
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